Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
Eric D BatemanDavid J PriceHao-Chien WangAdel KhattabPatricia SchonffeldtAngelina CatanzaritiRalf J P van der ValkMaarten J H I BeekmanPublished in: The European respiratory journal (2021)
This study indicates an association between high SABA prescriptions and poor clinical outcomes across a broad range of countries, healthcare settings and asthma severities, providing support for initiatives to improve asthma morbidity by reducing SABA over-reliance.